New drug combo aims to outsmart Platinum-Resistant ovarian cancer
NCT ID NCT05198804
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called ZN-c3 (azenosertib), either alone or combined with niraparib, in 117 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find safe doses and see if the drugs can shrink tumors. It is an early-stage trial, so while promising, it is not yet proven as a standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Azenosertib (ZN-c3) and niraparib
- What this could lead to
- If successful, this could provide a new treatment option for women with ovarian cancer that no longer responds to platinum-based chemotherapy.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with only 117 participants, so results may not apply to all patients. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arizona Oncology Associates (Wilmot HOPE) - USOR
Tucson, Arizona, 85711, United States
-
Centre Georges François Leclerc
Dijon, France
-
Centre Hospitalier Lyon Sud
Saint-Genis-Laval, France
-
Centre Oscar Lambret
Lille, France
-
EDOG - Institut Claudius Regaud
Toulouse, France
-
ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, France
-
Institut Gustave Roussy
Villejuif, France
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
MD Anderson Cancer Center, Gynecologic Oncology Center
Texas City, Texas, 77030, United States
-
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
Optimum Clinical Research Group- Women's Oncology
Albuquerque, New Mexico, 87109, United States
-
Rocky Mountain Cancer Centers
Aurora, Colorado, 80012, United States
-
Rutgers New Jersey Medical School
Newark, New Jersey, 07103, United States
-
Spectrum Health System
Grand Rapids, Michigan, 49503, United States
-
Texas Oncology-Fort Worth Cancer Center
Fort Worth, Texas, 76104, United States
-
The Blavatnik Family - Chelsea Medical Center at Mount Sinai
New York, New York, 10011, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
-
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, 97401, United States
-
Women and Infants Hospital of Rhode Island
Providence, Rhode Island, 02905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can heated chemotherapy improve ovarian cancer outcomes?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?